1) Jameson JL, Kasper DL, Longo DL, et al. Harrison's principles of internal medicine, 20th ed. New York: The McGraw-Hill Companies, 2018;1119-20.
2) Ezer N, Benedetti A, Darvish-Zargar M, Menzies D. Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis 2013;17:447-55.
3) Lee EJ, Kim SJ, Choung HK, et al. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol 2008;28:269-77.
4) Schild HS, Fox BC. Rapid-onset reversible ocular toxicity from ethambutol therapy. Am J Med 1991;90:404-6.
5) Derka H. Does a correlation exist between Myambutol dosage and occurrence of optic neuritis. Ophthalmologica 1975;171:123-31.
6) Jang BL. Neuro-ophthalmology, 3rd ed. Seoul: Ilchokak Publishing Co, 2017;290.
7) Carr RE, Henkind P. Ocular manifestations of ethambutol, toxic amblyopia after administration of an experimental antituberculous drug. Arch Ophthalmol 1962;67:566-71.
8) Tsai RK, Lee YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther 1997;13:473-7.
9) Woung LC, Jou JR, Liaw SL. Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther 1995;11:411-9.
10) Kim KL, Park SP. Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level. Cutan Ocul Toxicol 2016;35:228-32.
11) Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol 2009;93:1251-4.
12) Choi SY, Hwang JM. Optic neuropathy associated with ethambutol in Koreans. Korean J Ophthalmol 1997;11:106-10.
13) Chung JK, Park YB, Park SP. Visual function test for early detection of ethambutol-induced ocular toxicity. J Korean Ophthalmol Soc 2012;53:694-9.
14) Kim BK, Ahn M. The use of optical coherence tomography in patients with ethambutol-induced optic neuropathy. J Korean Ophthalmol Soc 2010;51:1107-12.
15) Dette TM, Spitznas M, Göbbels M, et al. Visually evoked cortical potentials for early detection of optic neuritis in ethambutol therapy. Fortschr Ophthalmol 1991;88:546-8.
16) Lee JH, Choi SB, Choi J. Regular ophthalmic examination of patients taking ethambutol. J Korean Ophthalmol Soc 2016;57:1939-45.
17) Yoon YH, Jung KH, Sadun AA, et al. Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol Appl Pharmacol 2000;162:107-14.
19) Lessell S. The histology and histochemistry of the rat's optic nerve and chiasm. Am J Ophthalmol 1977;84:681-8.
20) Han J, Byun MK, Lee J, et al. Longitudinal analysis of retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2015;253:2293-9.
21) Su L, Li Q, Zhu L, et al. Characterisation of macular superficial vessel density alteration in preclinical ethambutol-induced optic neuropathy using optical coherence tomography angiography. Br J Ophthalmol 2020;bjophthalmol-2020-317742.
22) Spaide RF, Klancnik JM Jr, Cooney MJ. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 2015;133:45-50.
24) Kinoshita J, Iwata N, Maejima T, et al. Retinal function and morphology in monkeys with ethambutol-induced optic neuropathy. Invest Ophthalmol Vis Sci 2012;53:7052-62.
25) Lee JY, Han J, Seo JG, et al. Diagnostic value of ganglion cell-inner plexiform layer for early detection of ethambutol-induced optic neuropathy. Br J Ophthalmol 2019;103:379-84.
26) Lee JY, Choi JH, Park KA, Oh SY. Ganglion cell layer and inner plexiform layer as predictors of vision recovery in ethambutol-induced optic neuropathy: a longitudinal OCT analysis. Invest Ophthalmol Vis Sci 2018;59:2104-9.
27) Vieira LM, Silva NF, Dias dos Santos AM, et al. Retinal ganglion cell layer analysis by optical coherence tomography in toxic and nutritional optic neuropathy. J Neuroophthalmol 2015;35:242-5.
28) Moon H, Yoon JY, Lim HT, Sung KR. Ganglion cell and inner plexiform layer thickness determined by spectral domain optical coherence tomography in patients with brain lesions. Br J Ophthalmol 2015;99:329-35.
29) Na JH, Sung KR, Baek S, et al. Detection of glaucoma progression by assessment of segmented macular thickness data obtained using spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2012;53:3817-26.
30) Kim YK, Hwang JM. Serial retinal nerve fiber layer changes in patients with toxic optic neuropathy associated with antituberculosis pharmacotherapy. J Ocul Pharmacol Ther 2009;25:531-5.
32) Sadun A. Mitochondrial optic neuropathies. J Neurol Neurosurg Psychiatry 2002;72:424-6.